Company news
Cyclerion Therapeutics, Inc. news in 2022
Cyclerion Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.
Cyclerion Concludes Unsolicited Proposal Is Not in The Best Interest of The Company
November 21, 2022
Cyclerion Announces Mitochondrial Disease-Focused Corporate Strategy
October 5, 2022
Cyclerion Announces CY6463 Clinical Pipeline Progress and Second Quarter 2022 Financial Results
August 8, 2022
Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in Patients with Cognitive Impairment Associated with Schizophrenia (CIAS)
July 27, 2022
Steven E. Hyman, M.D., Appointed to Cyclerion Therapeutics’ Board of Directors
July 25, 2022
Cyclerion Therapeutics Announces CY6463 Data Demonstrating Improved Cellular Energetics in Preclinical Models of Mitochondrial Disease
June 16, 2022
Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in MELAS Patients at UMDF Mitochondrial Medicine 2022 Symposium
June 9, 2022
Cyclerion Announces CY6463 Clinical Pipeline Progress and First Quarter 2022 Financial Results
May 3, 2022
Cyclerion Announces CY6463 Clinical Pipeline and Corporate Updates
February 23, 2022
Cyclerion Therapeutics Announces Initiation of Patient Dosing in CY6463 Phase 2a Study in Alzheimer’s Disease with Vascular Pathology
January 25, 2022
Decks in 2022
- Technical Presentation (July 2022)
Technical · 30 slides · Jul 28, 2022
- Investor Presentation (June 2022)
Investor deck · 63 slides · Jun 10, 2022